Form 4: Zivo Bioscience Director Boosts Stake with Share Purchase

Zivo Bioscience Director Alison A. Cornell purchased 11,709 shares of common stock at $8.54 per share, increasing her direct beneficial ownership to 279,481 shares.

Summary

• Alison A. Cornell, a Director of Zivo Bioscience, Inc. (ZIVO), acquired 11,709 shares of common stock.
• The transaction occurred on January 26, 2026, at a price of $8.54 per share.
• Following this purchase, Ms. Cornell directly beneficially owns a total of 279,481 shares of Zivo Bioscience common stock.
• The transaction was a purchase (Code P) and was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director's purchase of company stock, indicating confidence in the company's value and future prospects. This is generally viewed favorably by investors.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition increases insider ownership, potentially aligning management interests more closely with shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that significant positive developments are anticipated. This can sometimes lead to increased investor interest in the stock.

Related Party Transactions

• The purchase of 11,709 shares of common stock by Director Alison A. Cornell is considered a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's future, potentially boosting investor confidence.

Key Dates

Recommendation

While a director's purchase of shares is a positive signal, indicating insider confidence, a single transaction of this size typically doesn't warrant a 'buy' recommendation on its own. It reinforces a 'hold' position for existing investors and suggests potential for further investigation for new investors, as it implies management sees value at the current price.

Keywords

Zivo Bioscience, ZIVO, Insider Trading, Director Purchase, Common Stock, Beneficial Ownership, Form 4, SEC Filing